Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000635076 | SCV000756454 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2022-09-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002483802 | SCV002776271 | uncertain significance | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2022-03-09 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003144407 | SCV003828837 | uncertain significance | Hyperaldosteronism, familial, type IV | 2020-02-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004025453 | SCV004914949 | uncertain significance | Inborn genetic diseases | 2023-12-18 | criteria provided, single submitter | clinical testing | The c.5717C>T (p.P1906L) alteration is located in exon 33 (coding exon 32) of the CACNA1H gene. This alteration results from a C to T substitution at nucleotide position 5717, causing the proline (P) at amino acid position 1906 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |